MedTrace Logo

Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial

NCT05782777 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4310

Last updated 2026-01-26

No results posted yet for this study

Summary

This study sought to evaluate whether ezetimibe combination to high-intensity statin therapy will have more prominent beneficial effect compared to high-intensity statin monotherapy in patients who underwent coronary revascularization with newer generation drug-eluting stent (DES) implantation. Furthermore, the optimal OCT-based optimal expansion criteria as well as the efficacy and safety of newer generation will be investigated.

Conditions

  • Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation

Interventions

DRUG

ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)

The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.

DRUG

high-intensity statin monotherapy (atoravastatin 40mg)

The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Byeong-Keuk Kim · Severance Cardiovascular Hospital, Yonsei University Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-07
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05782777 on ClinicalTrials.gov